Filed under: Equities, Companies, US
The technology sector got more than its share of attention on the New York equities markets on Tuesday as Advanced Micro Devices announced that it has filed a lawsuit against Intel.
The suit charges that Intel forced clients to buy their chips rather than AMD’s product.
The suit comes after AMD’s complaint of anti-competitive practices by Intel to the European Commission and after a ruling by the Fair Trade Commission in Japan which found that Intel had violated anti-trust laws when it offered rebates to five Japanese companies on condition that they would limit purchases of chips made by AMD.
Two investigations by the US Federal Trade Commission have been closed without finding any wrongdoing.
After news of the lawsuit was released, AMD’s shares rose 6.3 percent to $17.70, and Intel’s stock advanced by 1.8 percent to $26.33.
Overall in New York, the Dow Jones Industrial Average rose 1.1 percent to 10,405.63, the S&P 500 was up 0.9 percent to 1,201.57, and the Nasdaq Composite was up 1.2 percent to 2,069.89.
Factors in the advances included a drop in crude oil prices, news of a 3-year high in the consumer confidence index, and labor market conditions that look to be improving.
Airlines saw their shares gain value on the news that oil prices were declining. Delta Air Lines gained 12.8 percent to $3.97, AMR was up 9.3 percent to $12.3, and Air Tran Holdings rose 6.1 percent to $9.47.
Some energy stocks declined as investors interpreted lower oil prices as a threat to profits. Amerada Hess lost 3.8 percent to $106.26, while Marathon Oil fell 2.9 percent to $53.96.
>> Discuss this on the new Finance Markets messageboards
Permalink: AMD action helps NYSE technology stock rally
Filed under: Companies, Americas
Brazil is threatening to break the patent on an anti-retroviral drug for the treatment of AIDS if Abbot Laboratories, the holder of the patent, will not lower the price of the drug.
At the same time, the Brazilian government is in talks with two other US drug companies, Merck and Gilead Sciences, over the prices of their AIDS drugs.
Brazilian health minister Humberto Costa has said that if those companies will not cut the prices on their drugs, Brazil might break the patents on them as well.
Mr. Costa insisted that if Brazil does take this action, it will do so because it is in the “public interest.”
An official of a US industry lobby, the Pharmaceutical Research and Manufacturers of America, called the threat “troubling”, and Abbot Laboratories said that if Brazil begins to manufacture the drug itself, there could be a negative impact on the development of new drugs to treat not only AIDS but all diseases.
The World Trade Organization allows countries to break patents in circumstances of national emergency, but critics of Brazil’s potential move say that isn’t the case here and that Brazil is spending less on drugs to treat AIDS than it was five years ago.
Brazil wants Abbot to cut the price on the drug in question, Kaltera, by 42 percent. Abbot charges $1.17 per pill for the drug, but Brazil claims that a state owned laboratory could sell the drug for 68 cents per pill.
>> Discuss this on the new Finance Markets messageboards
Permalink: Brazil threatens action over AIDS drugs
« Previous Page — Next Page »
|